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Dementia: timely diagnosis and early intervention
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Dementia describes a clinical syndrome that encompasses
difficulties in memory, language, and behaviour that leads to
impairments in activities of daily living. Alzheimer’s disease
is the most common subtype of dementia, followed by vascular
dementia, mixed dementia, and dementia with Lewy bodies.
Because the global population is rapidly ageing, dementia has
become a concern worldwide1; the illness places considerable
burden on individuals and their families and also on health and
social care provision.
By 2050 an estimated 135 million people worldwide will have
dementia. In 2010 the global cost of dementia care was estimated
at $604bn (£396bn; €548bn) and estimated to increase to $1tr
by 2030.1 Of all chronic diseases, dementia is one of the most
important contributors to dependence and disability.2 3 In the
absence of a cure, a professional belief that nothing can be done
has contributed to delays in diagnosis.4 However, increasing
evidence showing that dementia may be preventable1 5 has led
to an international focus on earlier diagnosis and intervention.6
This review aims to summarise current evidence and best
practice in the diagnosis and early intervention in dementia care.
Why is timely diagnosis important?
In some countries the introduction of a national dementia
strategy has led to greater emphasis on earlier diagnosis,
although population based screening is not recommended as
dementia does not fulfil the criteria of a condition suitable for
screening.7With evidence from large longitudinal cohort studies
showing that the prevalence of dementia is declining globally,
there is now greater emphasis on prevention and risk reduction.1 5
In England, policy has rightly or wrongly influenced the
introduction of case finding in high risk groups—including
people over 75 years of age, as age is the strongest risk factor
for dementia—and those with high vascular risk, Parkinson’s
disease, and learning disabilities.8 The policy comprises
proactive memory assessment of people in both primary care
and acute hospital settings who may not have symptoms;
however, there is little evidence that such initiatives, which
inevitably lead to increased referrals to specialist services, are
cost effective and whether they are distressing to patients.4 6
How can clinicians recognise dementia?
Diagnosing dementia can be difficult owing to its insidious
onset, symptoms resembling “normal ageing” memory loss, and
a diversity of other presenting symptoms—for example,
difficulty in finding words or making decisions.10 An
individual’s ability to accommodate, compensate, or even deny
his or her symptoms in the early stages should also be
considered. The individual’s family may also have noticed
difficulties in communication and personality or mood changes;
family concern is of particular importance.9 Increasing frequency
of patients’ visits to their general practice, missed appointments,
or confusion over drugs may also be warning signs.8
Diagnosis of subtype is important given differences in
management, disease course, and outcomes for different
dementias; awareness of early symptoms in less common
dementias can assist generalists in deciding to which specialist
services patients are referred (box 1). Duration over which
symptoms have developed is also important, with Alzheimer’s
disease tending to have a more insidious onset than vascular
dementia.
How is dementia diagnosed?
The role of primary care
General practitioners are often the first point of contact for
patients who are worried that they may have dementia. The role
of primary care is to exclude a potentially treatable illness or
reversible cause of the “dementia”—for example, depression,
vitamin B12 deficiency, or thyroid disturbance; refer for specialist
assessment, especially those with unusual symptoms
(neurological, psychiatric, or behavioural changes) or those with
major risk factors (for example, important medical
comorbidities, psychosocial problems, harm to self); and ensure
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The bottom line
• Dementia is a major global health problem; in the absence of a cure there is increasing focus on risk reduction, timely diagnosis, and
early intervention
• Primary and secondary care doctors play complementary roles in dementia diagnosis; differential diagnoses include cognitive impairment
due to normal ageing and depression
• Cost effective drug (acetylcholinesterase inhibitors) and non-drug interventions such as cognitive stimulation therapy exist that help
to delay cognitive deterioration and improve quality of life; information provision and practical support are also important
• Discussions about a person’s wishes for future care should occur at an early stage of illness while the person has mental capacity
• Family carers of people with dementia are at high risk of physical and mental illness as a consequence of caring and they require
equal attention and support
Sources and selection criteria
We searched for articles through Medline, PubMed, and the Cochrane database of systematic reviews from January 2006 to December
2014—the period after publication of the current UK national dementia guidance9—using the search terms “dementia”, “Alzheimer’s”, “carer”,
and “caregiver”. Additional searches were carried out for specific subsections—for example, “pharmacologic treatment” and “non-pharmacologic
interventions/strategies/treatment”. Where possible, we focused on systematic reviews, meta-analyses, and high quality randomised controlled
trials. We included only articles in English and excluded those published in non-peer reviewed journals. Recommendations in this review
are derived from the most recent international and UK national guidance9 on evidence based practice in dementia care and the authors’
interpretation of the included evidence.
Patient and public involvement
Patient and public involvement in this clinical review has been achieved through several processes: the inclusion of patients and the public
in the groups responsible for developing the national guidelines referenced in this review; liaising with patient and public representatives
from the National Institute of Health Research Dementia and Neurodegenerative Diseases Research Network who contributed to systematic
reviews included in this review4 9; and asking the UK Alzheimer’s Society to comment on the final draft of the paper and provide up to date
information resources for patients and carers.
Box 1 Examples of less common dementias and their early presenting symptoms
Vascular dementia
• Wide range of signs and symptoms depending on extent, location, and severity of the cerebrovascular disease
• Symptoms can develop abruptly after a stroke or more insidiously with small vessel disease
• Memory loss can be a feature but typically is less noticeable than in Alzheimer’s disease. Language, information processing, decision
making, and visuospatial deficits can also be found
• Mood changes and apathy are common symptoms; can co-occur with Alzheimer’s disease and this is termed mixed dementia
Frontotemporal dementias
• More common in younger age groups (50-60 years)
• The most common clinical type is behavioural variant frontotemporal dementia, with changes in personality and behaviour. Disinhibition
and impulsiveness can be features. Memory function is typically intact early on
Dementia with Lewy bodies
• Complex visual hallucinations are a key feature. In the early stages they may only occur during periods of physical stress (for example,
infections) or at night time and may be followed by more subtle visuoperceptual symptoms—for example, illusions
• Parkinsonism (tremor, slowed movements, postural instability, shuffling gait) is also a feature. Tremor may be less evident, but people
with early dementia with Lewy bodies may be slower in movements and more prone to falls
• Fluctuations or noticeable variations in cognitive function can occur and can be difficult to separate from delirium
• Autonomic symptoms may occur—for example, postural hypotension
• Sleep disturbances such as rapid eye movement sleep behaviour disorder (shouting out or moving while asleep) can occur many
years before the onset of dementia
Parkinson’s disease with dementia
• As many as 80% of patients with Parkinson’s develop dementia
• Symptoms are similar to those of dementia with Lewy bodies, although motor Parkinson’s symptoms typically predate cognitive and
psychiatric symptoms by more than a year
Posterior cortical atrophy
• A less common form of Alzheimer’s disease, which tends to affect younger people (50s and 60s)
• Visual agnosias (difficulties with recognising faces, objects, or perceiving more than one object at a time), apraxias (motor planning
difficulties), acalculia (difficulty with calculation), and alexia (difficulty reading) are symptoms
• Memory typically preserved early on
Other uncommon to rare causes of dementia
• Alcohol related dementia, Creutzfeldt-Jakob disease, HIV related cognitive impairment, Huntington’s chorea, corticobasal syndrome,
movement related dementias (for example, progressive supranuclear palsy), multiple sclerosis, Niemann-Pick disease type C, normal
pressure hydrocephalus
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patients who have mild cognitive impairment (objective
cognitive loss not affecting function and daily living activities)
are followed up in primary care, and, if their symptoms become
more severe, re-referred for specialist assessment.
Initial assessment should include a careful history from both
the patient and the main carer, with particular emphasis on
disturbance of cognitive function and activities of daily living.
A physical examination should be undertaken to look for any
focal neurological signs and exclude any visual or auditory
problems. Baseline investigations and a brief cognitive
assessment, using one of the many tools available (box 2),
should also be carried out before referral to secondary care.9
The mini-mental state examination16 has traditionally been
recommended as the brief cognitive assessment tool of choice,
although copyright restrictions are influencing its use in practice.
The tools listed in box 2 have been found to be as clinically and
psychometrically robust as the mini-mental state examination17;
a clock drawing test may be added to the assessment if it is not
already incorporated into the tool.18 The Addenbrooke’s
cognitive examination,19 especially the revised version, has
superior diagnostic accuracy to the mini-mental state
examination but takes about 25 minutes to complete and has
better accuracy in moderate to high prevalence settings.20 No
one brief cognitive assessment tool is more accurate than another
and all are inadequate for assessing early or subtle changes,
with scores affected by factors such as education. Mini-mental
state examination scores are used to indicate the severity of
Alzheimer’s disease: mild, scores 21-26; moderate, scores 10-20;
moderately severe, scores 10-14; severe, scores less than 10.
Depression masquerading as dementia is probably the most
common differential diagnosis and should always be considered;
however, they can coexist and depressionmay precede dementia.
If suspected, a trial of antidepressants may be indicated, with
reassessment of the individual’s capabilities and cognitive
function 6-8 weeks later.
The role of secondary care
Primary care is increasingly taking on a greater role in both the
assessment and the long term care of people with dementia; one
multicentre randomised controlled trial found no evidence that
specialist memory clinics were more effective than general
practice services in providing post-diagnostic support.21
Secondary services have an important role in defining the
dementia subtype, dealing with more complex cases, and
stratifying which patients with mild cognitive impairment are
at greatest risk of developing dementia and most in need of
follow-up.
What are the roles of imaging and other
investigations?
Imaging, in particular structural scanning (computed tomography
or magnetic resonance imaging), is recommended as part of the
investigations of people with suspected dementia in UK,9
European,22 and US guidelines.23 Imaging is now also embedded
in several modern diagnostic criteria for different dementias,
including Alzheimer’s disease and dementia with Lewy
bodies.24-26 In modern dementia imaging there is now less focus
on “excluding” reversible causes of dementia (for example,
tumours) and more on determination of subtype. Structural
imaging, particularly magnetic resonance imaging, can also help
clarify whether a vascular disease is contributing to the cognitive
impairment and thus whether strict adherence to treatment
guidance for vascular risks is warranted.
In the United Kingdom, functional neuroimaging, including
hexamethylpropyleneamine oxime (HMPAO) single photon
emission computed tomography (SPECT) and
[18F]fluoro-2-deoxy-D-glucose positron emission tomography
(FDG-PET), is available but usually used as a second line
approach to assist with subtype diagnoses, particularly where
the diagnosis is in doubt. Dopaminergic iodine-123-radiolabelled
2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)
nortropane (FP-CIT) SPECT imaging is licensed in Europe and
in a number of other countries for the diagnosis of dementia
with Lewy bodies and may also be helpful where the clinical
diagnosis of dementia with Lewy bodies is not clear.27
What new investigations are emerging in
the diagnosis of dementia?
Cerebrospinal fluid sampling is used to exclude inflammatory,
infective, and malignancy related causes of dementia and is
typically recommended in individuals with rapid cognitive
decline, unusual or neurological presentations, or cognitive
impairment at less than 55 years of age.28 More recently there
has been a focus on developing cerebrospinal fluid based
markers, such as β amyloid and tau, for changes in Alzheimer’s
disease that can predate the onset of the dementia, the so called
prodromal phase of Alzheimer’s disease. Although suchmarkers
have been incorporated into recent diagnostic criteria for
Alzheimer’s disease,25 26whether they are effective at predicting
those who will develop dementia29 and, more importantly,
practically acceptable, makes their widespread clinical use
challenging at present.
It is now possible to directly image amyloid in the brain using
several positron emission tomography radiotracers, and this
imaging techniquemay have a future role clinically in predicting
which people with mild cognitive impairment will develop
Alzheimer’s disease. However there is still major heterogeneity
in how these scans are interpreted. For example, a recent
meta-analysis found that although amyloid imaging has high
sensitivity (83-100%) in detecting people with mild cognitive
impairment who convert to Alzheimer’s disease related
dementia, diagnostic specificities varied considerably between
studies (46-88%).30
What constitutes best practice in early
intervention?
Discussing the diagnosis: saying the “D”
word
Health professionals can be reluctant to speak openly and
honestly with patients and their families about dementia, with
some refraining from using the “D” word.28 Although initially
discussing the diagnosis may be distressing, evidence suggests
most people prefer to know if they have dementia in order to
access appropriate support and treatment and to plan for the
future.4 31
What options are available after
diagnosis?
Drug interventions
Clinically and cost effective drugs for dementia are available;
the emphasis is to improve or maintain function after neuronal
damage rather than to alter the underlying pathogenesis leading
to the dementia syndrome. Two classes of drugs are currently
recommended for symptomatic (Alzheimer’s disease andmixed)
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Box 2 Investigations and brief cognitive assessment tools for dementia in primary care
Blood tests
Blood tests that should be ordered are: full blood count, erythrocyte sedimentation rate, urea and electrolytes, thyroid function, vitamin
B12, and folate. Midstream specimen of urine, chest radiography, and electrocardiography may also be needed where clinically appropriate
Brief cognitive assessment tools
General practitioner assessment of cognition11
Takes no longer than five minutes to administer and comprises two components: a six item cognitive assessment with the patient and
an informant questionnaire (if the cognitive assessment score is equivocal: 5-8 inclusive). Scores >8 are deemed to represent cognitive
impairment and <5 intact cognition. Sensitivity 82-85%; specificity 83-86%12
6 item cognitive impairment test13
Takes 3-4 minutes to perform and consists of six questions on orientation and memory, although the test may be susceptible to influences
of language and education. Scores of 0-7 are considered normal and ≥8 suggest cognitive impairment. Sensitivity 78.5-83%; specificity
77-100%12
Mini-cog assessment instrument14
Takes 2-4 minutes to complete and consists of two components, a three item recall and the clock drawing test. Cognitive impairment is
considered to be present if people are unable to recall any of the three items or if they recall only one or two items and draw an abnormal
clock. Sensitivity 76-99%; specificity 89-96%12
Memory impairment screen15
Takes around four minutes to complete and is a brief four item delayed free recall and cued recall memory impairment test. A score of
≤4 indicates possible dementia. Sensitivity 74-86%; specificity 96-97%12
dementia6 32: acetylcholinesterase inhibitors donepezil,
galantamine, and rivastigmine, and N-methyl-D-aspartic acid
receptor antagonists such as memantine. At present,
acetylcholinesterase inhibitors are the only recommended
options to manage mild to moderate Alzheimer’s disease and
there is no evidence that one is more efficacious than another33;
notwithstanding, a large randomised controlled trial has recently
shown that continued treatment with donepezil is associated
with cognitive benefits in moderate to severe dementia.34
Memantine has been approved for people with moderate to
severe Alzheimer’s disease or those with intolerance to
acetylcholinesterase inhibitors; it has also been used in mild
Alzheimer’s disease but the evidence for this is currently lacking
despite its frequent off-label use.35
Non-drug approaches
The evidence base is steadily increasing for non-drug
interventions in dementia care, although further research in
many areas is still needed.6 In a large systematic review
evaluating both drug and non-drug interventions in dementia
care, cognitive stimulation therapy was found to be as clinically
and cost effective as the acetylcholinesterase inhibitors36;
reminiscence therapy is also recommended in national
guidelines.9 However, the evidence base for innovative service
provision such as case management, whereby a case manager,
usually a nurse or social worker acts as the main care coordinator
between key stakeholders, including primary and secondary
care, is mixed.6 36 Although the evidence base for cost
effectiveness is low,37 specially developed assistive
technology—any device or system that allows an individual to
perform tasks that they would otherwise be unable to do, or
increases the ease and safety with which the task can be
performed—to help people with dementia is available and can
be useful in relieving carer anxiety and helping people with
dementia to remain living at home (www.atdementia.org.uk/).
Information provision
People with dementia and their families require emotional and
practical support to help them live as good a quality of life as
they can; the family doctor is in a key position to provide
ongoing support and advice once the diagnosis is confirmed.4 6
Voluntary organisations such as Alzheimer’s International
provide a wide range of information resources and practical
support for people living with all types of dementia (www.alz.
co.uk/). Signposting to local sources of support as well as social
services and respite care are integral to the consultation.
Listening to an individual patient’s difficulties and concerns
and providing simple cognitive and emotional strategies in the
primary care consultation are beneficial to both patients and
their families.
Discussing the future
One important area to be discussed in the earlier stages of
dementia, while people still have mental capacity, is personal
wishes for future care and also who shouldmake decisions when
the patients are no longer able to do so. In dementia, such
discussions—termed advance care planning—have been shown
to reduce inappropriate hospital admissions towards the end of
life, but the evidence base is weak.38 39 Discussions about
advance care planning require both sensitivity and honesty;
general practitioners or hospital specialists are well placed to
undertake these discussions if they have an established
relationship with the patient. After such conversations, patients
can formally record their wishes in several ways, including the
completion of an advance directive, or “living will” as it was
previously known (box 3).
Primary care doctors may find it difficult to assess the mental
capacity of an individual with dementia; mental capacity may
fluctuate with time and also with acute illness. In England, the
introduction of theMental Capacity Act in 2005 provided much
needed guidance for health and social care professionals on how
to undertake an assessment of capacity and to make decisions
in the best interests of adults who lack the mental capacity to
do so for themselves (box 4).
Caring for family carers
In the UK, two thirds of people with dementia live independently
in the community, with most of their care and support provided
by family and friends. Such informal carers are more likely to
experience depressed mood, to report a higher care “burden,”
and to have worse physical health than carers of people with
other long term conditions.40 They may grieve as their family
member loses functional and cognitive abilities, and as
companionship, affection, and intimacy are affected; this is
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Box 3 Outcomes of advance care planning discussions: international and national terminology
• Statement of wishes and preferences—this documents an individual’s wishes for future care and is not legally binding; in the UK this
is known as an advance statement
• An advance directive for refusal of treatment (or “living will”)—this is a statement of an individual’s refusal to receive specific medical
treatment in a predefined future situation. It is legally binding and comes into effect when a person loses mental capacity. In the UK,
this is known as an advance decision to refuse treatment
• A proxy decision maker or power of attorney—This is a legally binding document whereby an individual (“donor”) nominates another
(“attorney”) to make decisions on his or her behalf should he or she lose capacity. In England, following the Mental Capacity Act, this
is now known as a lasting power of attorney and there are two separate aspects to lasting power of attorney, one for an individual’s
health and welfare and a second for property and financial affairs
Box 4 Assessment of mental capacity (as derived from UK Mental Capacity Act 2005)
Two stage test for determining whether an individual has mental capacity to make a specific decision
1. Does the patient have an impairment or disturbance of function of the brain?
2. Regarding a specific decision, can the patient:
• understand the decision to be made?
• retain sufficient information to make an informed decision?
• use information appropriately?
• communicate their decision?
Practical tips for assessment of capacity:
• Information may need to be provided in different forms
• General practitioners may need to assess patients on several occasions—that is, if morning is the best time for them
• Record information and the two stages described above accurately in patient notes
• Refer to experts (old age psychiatry) if in doubt
termed a living bereavement. Notwithstanding the satisfaction
carers experience from caring, the support they receive and their
ability to seek help when needed influence how they cope.
Supporting informal carers, monitoring their health and
wellbeing, and providing or referring them for additional
practical and psychological support is another crucial role for
general practitioners and community care services.41
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Tips for non-specialists
• Occasional memory lapses are common as people get older, especially in the presence of stress, depression, and acute physical
illness; review the patient after appropriate treatment has been given or a reasonable length of time has elapsed
• If you suspect dementia, take a history from both the patient and the main family carer; the latter’s suspicions are often correct
• Be aware that certain groups of people are at greater risk of developing dementia—for example, those who have had a stroke and
those with Parkinson’s disease
• Early identification of modifiable risk factors for dementia may reduce the numbers of people developing dementia in later life
• Effective and useful treatments exist for people with dementia; have a low threshold for referring someone with suspicious symptoms
for a specialist memory assessment
• Assess both the physical and the mental health of the main family carer; supporting informal carers is an important part of dementia
care
Additional educational resources
Resources for healthcare professionals
Alzheimer’s Society. Assessing cognition in older people (www.alzheimers.org.uk/cognitiveassessment)—a practical toolkit for health
professionals
BMJ Group resources: BMJ Learning modules. (http://learning.bmj.com/learning/module-intro/dementia-primary-care)—describes the
management of dementia in primary care
BMJ Quality (http://quality.bmj.com)—four e-projects to improve quality of care in the areas of support for carers, antipsychotic drug
prescribing, timely diagnosis, and palliative care
Resources for patients and carers
Social Care Institute for Excellence. Dementia gateway (www/scie/org.uk/dementia)—web based information and e-learning resources
written by experts mainly for professional carers and supporters
Alzheimer’s Society. The dementia guide: living well after diagnosis (www.alzheimers.org.uk/dementiaguide or request copies at
publications@alzheimers.org.uk)—comprehensive practical information for people with dementia and families with a recent diagnosis.
Includes a free booklet, video case studies, and downloadable translations
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